WilmerHale Advises GentiBio in $157M Series A Funding

Download IconDownload Print IconPrint

WilmerHale Advises GentiBio in $157M Series A Funding

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On August 11, 2021, GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, announced it has closed a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, Novartis Venture Fund and Seattle Children’s Research Institute. The company’s unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory and allergic diseases using novel technologies that precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio has raised more than $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs. The Series A financing will enable GentiBio to advance its potential functional cure for Type 1 Diabetes to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. 

The WilmerHale team advising GentiBio consisted of Jason Kropp, Mark Nylen and Jahnvi Desai.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel